

Anti-FcRn (FCGRT & B2M) Antibody (Orilanolimab)

Introduction

Orilanolimab (SYNT001) is a humanized, deimmunized, FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of the IgG molecule. Orilanolimab prevents IgG IC from activating FcRn-mediated adaptive immune function. Orilanolimab disrupts IgG homeostasis and innate and adaptive immunity.

Product parameters

Alternative Names	SYNT1001, ALXN1830
Target Accession	P55899
Target	FcRn (FCGRT & B2M)
CAS number	2066544-85-0
Molecular Weight	144.6 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized FcRn (FCGRT) His+FcRn (B2M) at 2 ug/mL can bind Anti-FcRn (FCGRT & B2M) Reference Antibody (orilanolimab), EC50=0.0311 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

